Introdução
Esta página fornece uma análise abrangente do histórico conhecido de negociações internas de Nicole Vitullo. Insiders são oficiais, diretores ou investidores significativos em uma empresa. É ilegal para insiders realizarem negociações em suas próprias empresas baseados em informações específicas, não públicas. Isso não significa que seja ilegal para eles realizarem qualquer negociação em suas próprias empresas. No entanto, eles devem reportar todas as negociações à SEC através de um Formulário 4. Apesar dessas restrições, pesquisas acadêmicas sugerem que insiders - em geral - tendem a superar o mercado em suas próprias empresas.
Rentabilidade Média de Negociação
A rentabilidade média de negociação é o retorno médio de todas as compras de mercado abertas feitas pelo insider nos últimos três anos. Para calcular isso, examinamos cada compra de mercado aberto, não planejada, feita pelo insider, excluindo todas as negociações que foram marcadas como parte de um plano de negociação 10b5-1. Em seguida, calculamos o desempenho médio dessas negociações ao longo de 3, 6 e 12 meses, fazendo a média de cada uma dessas durações para gerar uma métrica de desempenho final para cada negociação. Finalmente, fazemos a média de todas as métricas de desempenho para calcular uma métrica de desempenho para o insider. Esta lista inclui apenas insiders que fizeram pelo menos três negociações nos últimos dois anos.
Se a rentabilidade de negociação deste insider é "N/A", então o insider ou não fez quaisquer compras de mercado aberto nos últimos três anos, ou as negociações que eles fizeram são muito recentes para calcular uma métrica de desempenho confiável.
Frequência de Atualização: Diariamente
Empresas com Posições Internas Reportadas
As declarações à SEC indicam que Nicole Vitullo reportou posses ou negociações nas seguintes empresas:
Como Interpretar os Gráficos
Os gráficos a seguir mostram o desempenho das ações dos a ativos ubsequentes a cada transação de mercado aberto, não planejada feita por Nicole Vitullo. Transações não planejadas são negociações que não foram feitas como parte de um plano de negociação 10b5-1. O desempenho das ações é representado como mudança percentual cumulativa no preço das ações. Por exemplo, se uma transação interna foi feita em 1 de janeiro de 2019, o gráfico mostrará a mudança percentual diária da segurança até o dia presente. Se o preço da ação passasse de $10 para $15 durante este período, a mudança percentual cumulativa no preço das ações seria de 50%. Uma mudança no preço de $10 para $20 seria de 100%, e uma mudança no preço de $10 para $5 seria de -50%.
Ultimamente, estamos tentando determinar quão estreitamente as negociações do interno correlacionam-se a retornos excessivos (positivos ou negativos) no preço da ação para ver se o interno está cronometrando suas transações para lucrar com informações internas. Considere a situação onde um interno estava fazendo isso. Nesta situação, esperaríamos (a) retornos positivos após compras, ou (b) retornos negativos após vendas. No caso de (a), o gráfico de COMPRA mostraria uma série de curvas ascendentes, indicando retornos positivos após cada transação de compra. No caso de (b), o gráfico de VENDA mostraria uma série de curvas descendentes, indicando retornos negativos após cada transação de venda.
No entanto, isso sozinho não é suficiente para tirar conclusões. Se, por exemplo, o preço da ação da empresa estivesse em uma escalada não cíclica ao longo de muitos anos, então esperaríamos que todos os gráficos pós-compra tivessem uma inclinação ascendente. Da mesma forma, declínios não cíclicos ao longo de muitos anos resultariam em gráficos pós-negociação inclinados para baixo. Nenhum desses gráficos sugeriria atividade de negociação interna.
O indicador mais forte seria uma situação em que o preço da ação fosse extremamente cíclico, e houvesse sinais positivos no gráfico de COMPRA e gráficos negativos no gráfico de VENDA. Esta situação seria altamente sugestiva de um interno que estava cronometrando transações para sua vantagem financeira.
Compras Internas ADYX / Adynxx, Inc. - Análise de Lucro de Curto Prazo
Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ADYX / Adynxx, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Máx |
Preço em Máx |
Lucro Máx ($) |
Retorno Máx (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Vendas Internas ADYX / Adynxx, Inc. - Análise de Perda de Curto Prazo
Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ADYX / Adynxx, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Mín |
Preço em Mín |
Máxima Perda Evitada ($) |
Máxima Perda Evitada (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Compras Internas ALDX / Aldeyra Therapeutics, Inc. - Análise de Lucro de Curto Prazo
Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ADYX / Adynxx, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Máx |
Preço em Máx |
Lucro Máx ($) |
Retorno Máx (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Vendas Internas ALDX / Aldeyra Therapeutics, Inc. - Análise de Perda de Curto Prazo
Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ADYX / Adynxx, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Mín |
Preço em Mín |
Máxima Perda Evitada ($) |
Máxima Perda Evitada (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Compras Internas ATRA / Atara Biotherapeutics, Inc. - Análise de Lucro de Curto Prazo
Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ADYX / Adynxx, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Vendas Internas ATRA / Atara Biotherapeutics, Inc. - Análise de Perda de Curto Prazo
Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ADYX / Adynxx, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Mín |
Preço em Mín |
Máxima Perda Evitada ($) |
Máxima Perda Evitada (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Compras Internas ATYR / aTyr Pharma, Inc. - Análise de Lucro de Curto Prazo
Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ADYX / Adynxx, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Máx |
Preço em Máx |
Lucro Máx ($) |
Retorno Máx (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Vendas Internas ATYR / aTyr Pharma, Inc. - Análise de Perda de Curto Prazo
Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ADYX / Adynxx, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Mín |
Preço em Mín |
Máxima Perda Evitada ($) |
Máxima Perda Evitada (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Compras Internas BNGO / Bionano Genomics, Inc. - Análise de Lucro de Curto Prazo
Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ADYX / Adynxx, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Máx |
Preço em Máx |
Lucro Máx ($) |
Retorno Máx (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018-08-23 | BNGO | Domain Partners VIII, L.P. | 15,000 | 6.1250 | 429 | 214.3750 | 91,875 | 35 | 82.5 | -56,565 | -61.57 |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Vendas Internas BNGO / Bionano Genomics, Inc. - Análise de Perda de Curto Prazo
Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ADYX / Adynxx, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Mín |
Preço em Mín |
Máxima Perda Evitada ($) |
Máxima Perda Evitada (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Compras Internas ESPR / Esperion Therapeutics, Inc. - Análise de Lucro de Curto Prazo
Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ADYX / Adynxx, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Máx |
Preço em Máx |
Lucro Máx ($) |
Retorno Máx (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-10-21 | ESPR | DOMAIN PARTERS VII L P | 500,000 | 20.0000 | 500,000 | 20.0000 | 10,000,000 | 210 | 115.3000 | 47,650,000 | 476.50 |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Vendas Internas ESPR / Esperion Therapeutics, Inc. - Análise de Perda de Curto Prazo
Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ADYX / Adynxx, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Compras Internas GKOS / Glaukos Corporation - Análise de Lucro de Curto Prazo
Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ADYX / Adynxx, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Máx |
Preço em Máx |
Lucro Máx ($) |
Retorno Máx (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Vendas Internas GKOS / Glaukos Corporation - Análise de Perda de Curto Prazo
Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ADYX / Adynxx, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Mín |
Preço em Mín |
Máxima Perda Evitada ($) |
Máxima Perda Evitada (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Compras Internas SNDX / Syndax Pharmaceuticals, Inc. - Análise de Lucro de Curto Prazo
Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ADYX / Adynxx, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Máx |
Preço em Máx |
Lucro Máx ($) |
Retorno Máx (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Vendas Internas SNDX / Syndax Pharmaceuticals, Inc. - Análise de Perda de Curto Prazo
Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ADYX / Adynxx, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Mín |
Preço em Mín |
Máxima Perda Evitada ($) |
Máxima Perda Evitada (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Compras Internas VCYT / Veracyte, Inc. - Análise de Lucro de Curto Prazo
Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ADYX / Adynxx, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Máx |
Preço em Máx |
Lucro Máx ($) |
Retorno Máx (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Vendas Internas VCYT / Veracyte, Inc. - Análise de Perda de Curto Prazo
Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ADYX / Adynxx, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Mín |
Preço em Mín |
Máxima Perda Evitada ($) |
Máxima Perda Evitada (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Histórico de Negociações Insider
Esta tabela mostra a lista completa de negociações insider realizadas por Nicole Vitullo conforme divulgadas para a Comissão de Valores Mobiliários (SEC).
| Data do Arquivo | Data da Transação | Formulário | Ticker | Ativo | Código | Ações | Ações Restantes | Variação Percentual |
Preço da Ação |
Valor da Transação |
Valor Restante |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-16 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
A - Award | 5,150 | 36,918 | 16.21 | ||||
| 2022-05-27 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 20,000 | 20,000 | |||||
| 2022-02-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 12,375 | 12,375 | |||||
| 2022-02-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
A - Award | 2,750 | 6,442 | 74.49 | ||||
| 2021-05-28 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
A - Award | 12,376 | 31,768 | 63.82 | ||||
| 2021-03-16 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
J - Other | 2,717 | 3,692 | 278.67 | ||||
| 2021-03-16 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
J - Other | -11,612 | 0 | -100.00 | ||||
| 2021-03-16 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
J - Other | -6,192 | 0 | -100.00 | ||||
| 2021-03-16 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
S - Sale | -4,250 | 0 | -100.00 | 15.87 | -67,448 | ||
| 2021-03-16 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
J - Other | 6,192 | 6,192 | |||||
| 2021-03-16 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
J - Other | -619,221 | 0 | -100.00 | ||||
| 2021-01-20 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 16,500 | 16,500 | |||||
| 2020-11-06 |
|
4/A | MRNS |
MARINUS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 150,000 | 150,000 | |||||
| 2020-05-29 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
A - Award | 6,106 | 19,392 | 45.96 | ||||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -42,000 | 0 | -100.00 | ||||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -30,000 | 0 | -100.00 | ||||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -30,000 | 0 | -100.00 | ||||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -30,000 | 0 | -100.00 | ||||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -25,000 | 0 | -100.00 | ||||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -25,000 | 0 | -100.00 | ||||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -20,000 | 0 | -100.00 | ||||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -20,000 | 0 | -100.00 | ||||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -50,000 | 0 | -100.00 | ||||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -25,159 | 0 | -100.00 | 6.30 | -158,502 | ||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -3,393,382 | 0 | -100.00 | 6.30 | -21,378,307 | ||
| 2020-01-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -36,431 | 0 | -100.00 | 6.30 | -229,515 | ||
| 2020-01-10 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 100,000 | 100,000 | |||||
| 2019-08-08 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Warrants to Purchase Common Stock |
P - Purchase | 187,500 | 187,500 | 4.00 | 750,000 | 750,000 | ||
| 2019-08-08 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Common Stock |
P - Purchase | 250,000 | 813,433 | 44.37 | 4.00 | 1,000,000 | 3,253,732 | |
| 2019-05-31 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
A - Award | 4,967 | 13,286 | 59.71 | ||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
| 2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
| 2019-03-21 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | 1,356 | 8,319 | 19.47 | ||||
| 2019-03-21 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | -17,790 | 0 | -100.00 | ||||
| 2019-03-21 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -1,700 | 0 | -100.00 | 45.25 | -76,925 | ||
| 2019-03-21 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -13,629 | 1,700 | -88.91 | 44.66 | -608,671 | 75,922 | |
| 2019-03-21 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | 17,790 | 17,790 | |||||
| 2019-03-21 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | -1,101,080 | 0 | -100.00 | ||||
| 2019-02-28 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 35,000 | 35,000 | |||||
| 2019-01-25 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 42,000 | 42,000 | |||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Warrants to Purchase Common Stock |
P - Purchase | 15,000 | 15,000 | |||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series B Preferred Stock |
C - Conversion | -6,810,098 | 0 | -100.00 | ||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Convertible Promissory Note |
C - Conversion | 0 | ||||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series D-1 Preferred Stock |
C - Conversion | -3,682,919 | 0 | -100.00 | ||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series D Preferred Stock |
C - Conversion | -6,396,105 | 0 | -100.00 | ||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series C Preferred Stock |
C - Conversion | -5,426,808 | 0 | -100.00 | ||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series B-1 Preferred Stock |
C - Conversion | -2,986,762 | 0 | -100.00 | ||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
P - Purchase | 15,000 | 943,878 | 1.61 | 6.12 | 91,875 | 5,781,253 | |
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
C - Conversion | 337,694 | 929,878 | 57.03 | 4.59 | 1,550,015 | 4,268,140 | |
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
C - Conversion | 591,184 | 591,184 | |||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series B Preferred Stock |
C - Conversion | -50,532 | 0 | -100.00 | ||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Convertible Promissory Note |
C - Conversion | 0 | ||||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series D-1 Preferred Stock |
C - Conversion | -27,328 | 0 | -100.00 | ||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series D Preferred Stock |
C - Conversion | -47,460 | 0 | -100.00 | ||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series C Preferred Stock |
C - Conversion | -40,268 | 0 | -100.00 | ||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series B-1 Preferred Stock |
C - Conversion | -22,161 | 0 | -100.00 | ||||
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
C - Conversion | 2,505 | 6,891 | 57.11 | 4.59 | 11,498 | 31,630 | |
| 2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
C - Conversion | 4,386 | 4,386 | |||||
| 2018-08-27 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Common Stock |
P - Purchase | 1,648,359 | 5,634,329 | 41.35 | 1.82 | 3,000,013 | 10,254,479 | |
| 2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
| 2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
| 2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
| 2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
| 2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
| 2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
| 2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
| 2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
| 2018-06-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | 3,846 | 6,963 | 123.39 | ||||
| 2018-06-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | -21,471 | 0 | -100.00 | ||||
| 2018-06-04 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | 5,000 | 36,431 | 15.91 | ||||
| 2018-06-04 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | -25,000 | 0 | -100.00 | ||||
| 2018-05-25 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 10,100 | 10,100 | |||||
| 2018-02-13 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 30,000 | 30,000 | |||||
| 2018-01-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | 645 | 3,177 | 25.47 | ||||
| 2018-01-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | -8,500 | 0 | -100.00 | ||||
| 2018-01-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -11,674 | 15,329 | -43.23 | 71.79 | -838,076 | 1,100,469 | |
| 2018-01-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Common Stock |
M - Exercise | -1,193 | 0 | -100.00 | ||||
| 2018-01-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Common Stock |
M - Exercise | -70,042 | 0 | -100.00 | ||||
| 2018-01-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
F - Taxes | -117 | 27,003 | -0.43 | 71.82 | -8,403 | 1,939,355 | |
| 2018-01-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
M - Exercise | 1,193 | 27,120 | 4.60 | 6.99 | 8,339 | 189,569 | |
| 2018-01-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
F - Taxes | -6,814 | 1,101,080 | -0.62 | 71.82 | -489,381 | 79,079,566 | |
| 2018-01-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
M - Exercise | 70,042 | 1,107,894 | 6.75 | 6.99 | 489,594 | 7,744,179 | |
| 2018-01-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | 8,500 | 8,500 | |||||
| 2018-01-26 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | -850,000 | 1,037,852 | -45.02 | ||||
| 2018-01-24 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
J - Other | 2,250 | 46,450 | 5.09 | ||||
| 2018-01-24 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
J - Other | -2,250 | 3,900 | -36.59 | ||||
| 2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Redeemable Convertible Preferred Stock |
C - Conversion | -368 | 0 | -100.00 | ||||
| 2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
A - Award | 282 | 25,730 | 1.11 | ||||
| 2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 12,444 | 25,448 | 95.69 | 3.19 | 39,696 | 81,179 | |
| 2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Redeemable Convertible Preferred Stock |
C - Conversion | -49,632 | 0 | -100.00 | ||||
| 2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
A - Award | 37,890 | 3,469,029 | 1.10 | ||||
| 2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 1,678,432 | 3,431,139 | 95.76 | 3.19 | 5,354,198 | 10,945,333 | |
| 2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -988,285 | 0 | -100.00 | ||||
| 2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -47,963 | 0 | -100.00 | ||||
| 2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -15,731 | 0 | -100.00 | ||||
| 2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Warrant to Purchase Common Stock |
D - Sale to Issuer | -20,150 | 0 | -100.00 | ||||
| 2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Warrant to Purchase Common Stock |
D - Sale to Issuer | -20,150 | 0 | -100.00 | ||||
| 2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -1,857,036 | 0 | -100.00 | ||||
| 2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -7,333 | 0 | -100.00 | ||||
| 2017-12-08 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | 2,472 | 2,472 | |||||
| 2017-12-08 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | -32,560 | 0 | -100.00 | ||||
| 2017-12-08 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -9,326 | 25,927 | -26.45 | 53.85 | -502,205 | 1,396,169 | |
| 2017-12-08 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | 3,291 | 32,560 | 11.24 | ||||
| 2017-12-08 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | -329,083 | 1,887,852 | -14.84 | ||||
| 2017-12-08 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 35,000 | 35,000 | |||||
| 2017-09-11 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
J - Other | 1,650 | 44,200 | 3.88 | ||||
| 2017-09-11 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
J - Other | -1,650 | 6,150 | -21.15 | ||||
| 2017-08-14 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Warrants to Purchase Common Stock |
M - Exercise | -20,706 | 0 | -100.00 | ||||
| 2017-08-14 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Warrants to Purchase Common Stock |
M - Exercise | -2,790,539 | 0 | -100.00 | ||||
| 2017-08-14 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
F - Taxes | -12,726 | 25,159 | -33.59 | 5.06 | -64,394 | 127,305 | |
| 2017-08-14 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
M - Exercise | 20,706 | 37,885 | 120.53 | 3.11 | 64,447 | 117,917 | |
| 2017-08-14 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
F - Taxes | -1,714,954 | 3,393,382 | -33.57 | 5.06 | -8,677,667 | 17,170,513 | |
| 2017-08-14 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
M - Exercise | 2,790,539 | 5,108,336 | 120.40 | 3.11 | 8,685,553 | 15,899,696 | |
| 2017-04-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 14,000 | 14,000 | |||||
| 2017-04-12 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Redeemable Convertible Preferred Stock |
P - Purchase | 49,632 | 49,632 | 100.00 | 4,963,200 | 4,963,200 | ||
| 2017-04-12 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Redeemable Convertible Preferred Stock |
P - Purchase | 368 | 368 | 100.00 | 36,800 | 36,800 | ||
| 2017-01-19 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 10,500 | 10,500 | |||||
| 2017-01-19 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
A - Award | 4,500 | 7,800 | 136.36 | ||||
| 2017-01-19 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 30,000 | 30,000 | |||||
| 2016-11-04 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | 17,695 | 0 | -100.00 | ||||
| 2016-11-04 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | 1,071 | 0 | -100.00 | ||||
| 2016-11-04 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | 1,996 | 0 | -100.00 | ||||
| 2016-11-04 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -38,094 | 0 | -100.00 | 28.35 | -1,079,965 | ||
| 2016-11-03 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -3,553,322 | 0 | -100.00 | 28.35 | -100,736,679 | ||
| 2016-11-03 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -47,613 | 0 | -100.00 | 28.35 | -1,349,829 | ||
| 2016-11-03 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -1,657 | 0 | -100.00 | 28.35 | -46,976 | ||
| 2016-11-03 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -285,679 | 0 | -100.00 | 28.35 | -8,099,000 | ||
| 2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series C Preferred Stock |
C - Conversion | -14,271 | 0 | -100.00 | ||||
| 2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series B Preferred Stock |
C - Conversion | -20,583 | 0 | -100.00 | ||||
| 2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series A Preferred Stock |
C - Conversion | -11,083 | 0 | -100.00 | ||||
| 2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Common Stock |
C - Conversion | 49,570 | 49,570 | |||||
| 2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series E Preferred Stock |
C - Conversion | -482,326 | 0 | -100.00 | ||||
| 2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series D Preferred Stock |
C - Conversion | -597,207 | 0 | -100.00 | ||||
| 2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series C Preferred Stock |
C - Conversion | -836,722 | 0 | -100.00 | ||||
| 2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series B Preferred Stock |
C - Conversion | -1,206,836 | 0 | -100.00 | ||||
| 2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series A Preferred Stock |
C - Conversion | -649,835 | 0 | -100.00 | ||||
| 2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Common Stock |
C - Conversion | 3,985,970 | 3,985,970 | |||||
| 2016-09-13 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
J - Other | -1,943,109 | 0 | -100.00 | ||||
| 2016-08-05 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 7,700 | 7,700 | |||||
| 2016-08-05 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
A - Award | 3,300 | 3,300 | |||||
| 2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -129 | 3,039 | -4.07 | 8.15 | -1,051 | 24,768 | |
| 2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -32 | 3,168 | -1.00 | 8.71 | -279 | 27,593 | |
| 2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -84 | 3,200 | -2.56 | 8.82 | -741 | 28,224 | |
| 2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -81,094 | 1,943,109 | -4.01 | 8.15 | -660,916 | 15,836,338 | |
| 2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -19,718 | 2,024,203 | -0.96 | 8.71 | -171,744 | 17,630,808 | |
| 2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -52,216 | 2,043,921 | -2.49 | 8.82 | -460,545 | 18,027,383 | |
| 2016-07-12 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Stock Option (Right to Buy) |
D - Sale to Issuer | -14,000 | 0 | -100.00 | ||||
| 2016-07-12 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Stock Option (Right to Buy) |
D - Sale to Issuer | -14,000 | 0 | -100.00 | ||||
| 2016-07-12 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Stock Option (Right to Buy) |
D - Sale to Issuer | -28,000 | 0 | -100.00 | ||||
| 2016-07-12 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Warrant to Purchase Common Stock |
D - Sale to Issuer | -85,777 | 0 | -100.00 | ||||
| 2016-07-12 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Warrant to Purchase Common Stock |
D - Sale to Issuer | -32,091 | 0 | -100.00 | ||||
| 2016-07-12 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Warrant to Purchase Common Stock |
D - Sale to Issuer | -44,495 | 0 | -100.00 | ||||
| 2016-07-12 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Common Stock |
D - Sale to Issuer | -5,867 | 0 | -100.00 | 30.25 | -177,477 | ||
| 2016-07-12 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Common Stock |
D - Sale to Issuer | -16,733 | 0 | -100.00 | 30.25 | -506,173 | ||
| 2016-07-12 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Common Stock |
D - Sale to Issuer | -2,378,924 | 0 | -100.00 | 30.25 | -71,962,451 | ||
| 2016-06-13 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 8,000 | 8,000 | |||||
| 2016-05-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -5,880 | 10,328 | -36.28 | 4.70 | -27,636 | 48,542 | |
| 2016-05-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -344,120 | 606,283 | -36.21 | 4.70 | -1,617,364 | 2,849,530 | |
| 2016-05-02 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -149,765 | 2,096,137 | -6.67 | 6.96 | -1,042,364 | 14,589,114 | |
| 2016-05-02 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -235 | 3,284 | -6.68 | 6.96 | -1,636 | 22,857 | |
| 2016-04-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -61 | 16,208 | -0.37 | 5.02 | -306 | 81,364 | |
| 2016-04-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -21 | 16,269 | -0.13 | 5.20 | -109 | 84,599 | |
| 2016-04-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -3,603 | 950,403 | -0.38 | 5.02 | -18,087 | 4,771,023 | |
| 2016-04-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -1,492 | 954,006 | -0.16 | 5.20 | -7,758 | 4,960,831 | |
| 2016-04-21 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -76 | 16,290 | -0.46 | 5.29 | -402 | 86,174 | |
| 2016-04-21 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -632 | 16,366 | -3.72 | 5.36 | -3,388 | 87,722 | |
| 2016-04-21 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -4,424 | 955,498 | -0.46 | 5.29 | -23,403 | 5,054,584 | |
| 2016-04-21 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -37,054 | 959,922 | -3.72 | 5.36 | -198,609 | 5,145,182 | |
| 2016-04-13 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -75 | 16,998 | -0.44 | 5.22 | -392 | 88,730 | |
| 2016-04-13 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -4,348 | 996,976 | -0.43 | 5.22 | -22,697 | 5,204,215 | |
| 2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -251 | 17,073 | -1.45 | 5.35 | -1,343 | 91,341 | |
| 2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -475 | 17,324 | -2.67 | 5.26 | -2,498 | 91,124 | |
| 2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -148 | 17,799 | -0.82 | 5.22 | -773 | 92,911 | |
| 2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -14,554 | 1,001,324 | -1.43 | 5.35 | -77,864 | 5,357,083 | |
| 2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -27,781 | 1,015,878 | -2.66 | 5.26 | -146,128 | 5,343,518 | |
| 2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -8,669 | 1,043,659 | -0.82 | 5.22 | -45,252 | 5,447,900 | |
| 2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series C-1 Preferred Stock |
C - Conversion | -360,640 | 0 | -100.00 | ||||
| 2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series B-1 Preferred Stock |
C - Conversion | -400,422 | 0 | -100.00 | ||||
| 2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 761,062 | 761,062 | |||||
| 2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series C-1 Preferred Stock |
C - Conversion | -2,674 | 0 | -100.00 | ||||
| 2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series B-1 Preferred Stock |
C - Conversion | -2,967 | 0 | -100.00 | ||||
| 2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 5,641 | 5,641 | |||||
| 2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series A-1 Preferred Stock |
C - Conversion | -13,925 | 0 | -100.00 | ||||
| 2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 13,925 | 13,925 | |||||
| 2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series B-1 Preferred Stock |
C - Conversion | -444,460 | 0 | -100.00 | ||||
| 2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series A-1 Preferred Stock |
C - Conversion | -1,299,394 | 0 | -100.00 | ||||
| 2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 1,743,854 | 1,743,854 | |||||
| 2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
| 2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
| 2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
| 2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
| 2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
| 2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
| 2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
| 2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
| 2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
| 2016-01-26 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 30,000 | 30,000 | |||||
| 2015-11-12 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
S - Sale | -370 | 17,179 | -2.11 | 10.31 | -3,815 | 177,115 | |
| 2015-11-12 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
S - Sale | -49,630 | 2,317,797 | -2.10 | 10.31 | -511,685 | 23,896,487 | |
| 2015-11-12 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
S - Sale | -1,325 | 17,549 | -7.02 | 10.43 | -13,820 | 183,036 | |
| 2015-11-12 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
S - Sale | -177,749 | 2,367,427 | -6.98 | 10.43 | -1,853,922 | 24,692,264 | |
| 2015-11-12 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
S - Sale | -2,375 | 18,874 | -11.18 | 10.01 | -23,774 | 188,929 | |
| 2015-11-12 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
S - Sale | -318,551 | 2,545,176 | -11.12 | 10.01 | -3,188,696 | 25,477,212 | |
| 2015-09-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
S - Sale | -69 | 21,249 | -0.32 | 8.22 | -567 | 174,667 | |
| 2015-09-29 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
S - Sale | -9,241 | 2,863,727 | -0.32 | 8.22 | -75,961 | 23,539,836 | |
| 2015-08-20 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -11,836 | 1,052,328 | -1.11 | 7.02 | -83,089 | 7,387,343 | |
| 2015-08-20 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -202 | 17,947 | -1.11 | 7.02 | -1,418 | 125,988 | |
| 2015-08-18 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | 31,431 | 31,431 | |||||
| 2015-08-18 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | -483,521 | 0 | -100.00 | ||||
| 2015-08-18 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
S - Sale | -37,843 | 21,318 | -63.97 | 7.51 | -284,201 | 160,098 | |
| 2015-07-22 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 6,300 | 6,300 | |||||
| 2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series F Preferred Stock |
C - Conversion | -286,983 | 0 | -100.00 | ||||
| 2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series E Preferred Stock |
C - Conversion | -589,100 | 0 | -100.00 | ||||
| 2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
C - Conversion | 876,083 | 876,083 | |||||
| 2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series F Preferred Stock |
C - Conversion | -2,130 | 0 | -100.00 | ||||
| 2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series E Preferred Stock |
C - Conversion | -4,371 | 0 | -100.00 | ||||
| 2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
C - Conversion | 6,501 | 6,501 | |||||
| 2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
| 2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
| 2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
| 2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
| 2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
| 2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
| 2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
| 2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
| 2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
| 2015-06-12 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Stock Option (Right to Buy) |
A - Award | 14,000 | 14,000 | |||||
| 2015-05-22 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | 222,630 | 483,521 | 85.33 | ||||
| 2015-05-22 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | -1,700,000 | 2,872,968 | -37.17 | ||||
| 2015-05-15 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 8,000 | 8,000 | |||||
| 2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series E Preferred Stock |
C - Conversion | -887,073 | 0 | -100.00 | ||||
| 2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series D Preferred Stock |
C - Conversion | -1,506,901 | 0 | -100.00 | ||||
| 2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series C Preferred Stock |
C - Conversion | -12,143,933 | 0 | -100.00 | ||||
| 2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
C - Conversion | 1,807,820 | 1,807,820 | |||||
| 2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series E Preferred Stock |
C - Conversion | -6,581 | 0 | -100.00 | ||||
| 2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series D Preferred Stock |
C - Conversion | -11,182 | 0 | -100.00 | ||||
| 2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series C Preferred Stock |
C - Conversion | -90,110 | 0 | -100.00 | ||||
| 2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
C - Conversion | 13,414 | 13,414 | |||||
| 2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -1,565 | 0 | -100.00 | ||||
| 2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series A Preferred Stock |
C - Conversion | -1,954 | 0 | -100.00 | ||||
| 2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 3,519 | 3,519 | |||||
| 2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series C Preferred Stock |
C - Conversion | -464,756 | 0 | -100.00 | ||||
| 2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -939,289 | 0 | -100.00 | ||||
| 2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series A Preferred Stock |
C - Conversion | -798,188 | 0 | -100.00 | ||||
| 2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 2,202,233 | 2,245,902 | 5,043.01 | ||||
| 2015-05-06 |
|
4 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
J - Other | 36,187 | 38,094 | 1,897.59 | ||||
| 2015-05-06 |
|
4 | TBRA |
Regado Biosciences Inc
Common Stock |
P - Purchase | 277,777 | 3,553,322 | 8.48 | 10.62 | 2,949,992 | 37,736,280 | |
| 2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
| 2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
| 2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
| 2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
| 2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
| 2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
| 2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
| 2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
| 2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
| 2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
| 2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
| 2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
| 2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
| 2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
| 2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
| 2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
| 2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
| 2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87,338 | ||||||||
| 2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87,338 | ||||||||
| 2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87,338 | ||||||||
| 2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87,338 | ||||||||
| 2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87,338 | ||||||||
| 2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87,338 | ||||||||
| 2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87,338 | ||||||||
| 2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -32,411 | 1,064,164 | -2.96 | 7.07 | -229,146 | 7,523,639 | |
| 2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -7,920 | 1,096,575 | -0.72 | 7.58 | -60,034 | 8,312,038 | |
| 2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -9,832 | 1,104,495 | -0.88 | 7.78 | -76,493 | 8,592,971 | |
| 2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -554 | 18,149 | -2.96 | 7.07 | -3,917 | 128,313 | |
| 2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -135 | 18,703 | -0.72 | 7.58 | -1,023 | 141,769 | |
| 2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -168 | 18,838 | -0.88 | 7.78 | -1,307 | 146,560 | |
| 2015-03-24 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | -350,000 | 2,216,935 | -13.63 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -2,827 | 0 | -100.00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock Warrant (Right to Buy) |
M - Exercise | -1,570 | 0 | -100.00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series C Preferred Stock |
C - Conversion | -102,282 | 0 | -100.00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -36,913 | 0 | -100.00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B Preferred Stock |
C - Conversion | -104,247 | 0 | -100.00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series A Preferred Stock |
C - Conversion | -12,578 | 0 | -100.00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -1,725 | 48,025 | -3.47 | 14.00 | -24,150 | 672,350 | |
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 2,827 | 49,750 | 6.02 | 8.54 | 24,143 | 424,865 | |
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -958 | 46,923 | -2.00 | 14.00 | -13,412 | 656,922 | |
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 1,570 | 47,881 | 3.39 | 8.54 | 13,408 | 408,904 | |
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
C - Conversion | 46,311 | 46,311 | |||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -165,790 | 0 | -100.00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock Warrant (Right to Buy) |
M - Exercise | -92,105 | 0 | -100.00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series C Preferred Stock |
C - Conversion | -7,252,144 | 0 | -100.00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -2,164,305 | 0 | -100.00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B Preferred Stock |
C - Conversion | -6,111,968 | 0 | -100.00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series A Preferred Stock |
C - Conversion | -737,422 | 0 | -100.00 | ||||
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
P - Purchase | 70,000 | 3,091,643 | 2.32 | 14.00 | 980,000 | 43,283,002 | |
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -101,132 | 3,021,643 | -3.24 | 14.00 | -1,415,848 | 42,303,002 | |
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 165,790 | 3,122,775 | 5.61 | 8.54 | 1,415,847 | 26,668,498 | |
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -56,185 | 2,956,985 | -1.86 | 14.00 | -786,590 | 41,397,790 | |
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 92,105 | 3,013,170 | 3.15 | 8.54 | 786,577 | 25,732,472 | |
| 2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
C - Conversion | 2,921,065 | 2,921,065 | |||||
| 2014-12-04 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 25,000 | 25,000 | |||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -165,790 | 0 | -100.00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock Warrant (Right to Buy) |
M - Exercise | -92,105 | 0 | -100.00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series C Preferred Stock |
C - Conversion | -7,252,144 | 0 | -100.00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -2,164,305 | 0 | -100.00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B Preferred Stock |
C - Conversion | -6,111,968 | 0 | -100.00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series A Preferred Stock |
C - Conversion | -737,422 | 0 | -100.00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
P - Purchase | 70,000 | 3,091,642 | 2.32 | 14.00 | 980,000 | 43,282,988 | |
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -101,132 | 3,021,642 | -3.24 | 14.00 | -1,415,848 | 42,302,988 | |
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 165,790 | 3,122,774 | 5.61 | 8.54 | 1,415,847 | 26,668,490 | |
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -56,185 | 2,956,984 | -1.86 | 14.00 | -786,590 | 41,397,776 | |
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 92,105 | 3,013,169 | 3.15 | 8.54 | 786,577 | 25,732,463 | |
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
C - Conversion | 2,921,064 | 2,921,064 | |||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -2,827 | 0 | -100.00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock Warrant (Right to Buy) |
M - Exercise | -1,570 | 0 | -100.00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series C Preferred Stock |
C - Conversion | -102,282 | 0 | -100.00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -36,913 | 0 | -100.00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B Preferred Stock |
C - Conversion | -104,247 | 0 | -100.00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series A Preferred Stock |
C - Conversion | -12,578 | 0 | -100.00 | ||||
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -1,725 | 48,023 | -3.47 | 14.00 | -24,150 | 672,322 | |
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 2,827 | 49,748 | 6.03 | 8.54 | 24,143 | 424,848 | |
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -958 | 46,921 | -2.00 | 14.00 | -13,412 | 656,894 | |
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 1,570 | 47,879 | 3.39 | 8.54 | 13,408 | 408,887 | |
| 2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
C - Conversion | 46,309 | 46,309 | |||||
| 2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
| 2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
| 2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
| 2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
| 2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
| 2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
| 2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
| 2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
| 2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
| 2014-11-18 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -6,250 | 0 | -100.00 | ||||
| 2014-11-18 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | -8,575 | 0 | -100.00 | ||||
| 2014-11-18 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -22,306 | 0 | -100.00 | ||||
| 2014-11-18 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -3,006,132 | 0 | -100.00 | ||||
| 2014-10-21 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
P - Purchase | 500,000 | 2,566,935 | 24.19 | 20.00 | 10,000,000 | 51,338,700 | |
| 2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -4,606 | 0 | -100.00 | ||||
| 2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -9,443 | 0 | -100.00 | ||||
| 2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Common Stock |
P - Purchase | 1,841 | 15,890 | 13.10 | 11.00 | 20,251 | 174,790 | |
| 2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Common Stock |
C - Conversion | 14,049 | 14,049 | |||||
| 2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -620,776 | 0 | -100.00 | ||||
| 2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -1,272,607 | 0 | -100.00 | ||||
| 2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Common Stock |
P - Purchase | 248,159 | 2,141,542 | 13.11 | 11.00 | 2,729,749 | 23,556,962 | |
| 2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Common Stock |
C - Conversion | 1,893,383 | 1,893,383 | |||||
| 2014-10-01 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 6,000 | 6,000 | |||||
| 2014-09-12 |
|
4 | VCYT |
VERACYTE, INC.
Common Stock |
J - Other | -300,000 | 2,763,294 | -9.79 | ||||
| 2014-09-11 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | 100,995 | 260,891 | 63.16 | ||||
| 2014-09-11 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | -1,200,000 | 4,572,968 | -20.79 | ||||
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -502 | 0 | -100.00 | ||||
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series D Preferred Stock |
F - Taxes | -1,386 | 0 | -100.00 | ||||
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series C Preferred Stock |
C - Conversion | -6,866 | 0 | -100.00 | ||||
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series B Preferred Stock |
C - Conversion | -3,238 | 0 | -100.00 | ||||
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
F - Taxes | -277 | 11,715 | -2.31 | 16.00 | -4,432 | 187,440 | |
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
M - Exercise | 502 | 11,992 | 4.37 | 8.79 | 4,413 | 105,410 | |
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
C - Conversion | 11,490 | 11,490 | |||||
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -67,755 | 0 | -100.00 | ||||
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series D Preferred Stock |
F - Taxes | -186,828 | 0 | -100.00 | ||||
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series C Preferred Stock |
C - Conversion | -925,479 | 0 | -100.00 | ||||
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series B Preferred Stock |
C - Conversion | -436,485 | 0 | -100.00 | ||||
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
F - Taxes | -37,224 | 1,579,323 | -2.30 | 16.00 | -595,584 | 25,269,168 | |
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
M - Exercise | 67,755 | 1,616,547 | 4.37 | 8.79 | 595,566 | 14,209,448 | |
| 2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
C - Conversion | 1,548,792 | 1,548,792 | |||||
| 2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -1,165 | 0 | -100.00 | ||||
| 2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series B Preferred Stock |
C - Conversion | -7,043 | 0 | -100.00 | ||||
| 2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series A Preferred Stock |
C - Conversion | -8,792 | 0 | -100.00 | ||||
| 2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 17,000 | 17,000 | |||||
| 2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -579,630 | 0 | -100.00 | ||||
| 2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series B Preferred Stock |
C - Conversion | -657,192 | 0 | -100.00 | ||||
| 2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series A Preferred Stock |
C - Conversion | -820,320 | 0 | -100.00 | ||||
| 2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
P - Purchase | 419,744 | 2,476,886 | 20.40 | 8.00 | 3,357,952 | 19,815,088 | |
| 2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 2,057,142 | 2,057,142 | |||||
| 2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
| 2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
| 2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
| 2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
| 2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
| 2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
| 2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
| 2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
| 2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
| 2014-06-13 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Stock Option (Right to Buy) |
A - Award | 14,000 | 14,000 | |||||
| 2014-05-22 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 8,575 | 8,575 | |||||
| 2014-05-16 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 5,000 | 5,000 | |||||
| 2014-05-07 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Convertible Promissory Note |
C - Conversion | 0 | ||||||
| 2014-05-07 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
C - Conversion | 21,250 | 1,973,389 | 1.09 | ||||
| 2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -3,882 | 0 | -100.00 | ||||
| 2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
C - Conversion | 9,208 | 9,208 | |||||
| 2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series B Preferred Stock Warrant (Right to Buy) |
M - Exercise | -60,576 | 0 | -100.00 | ||||
| 2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series B Preferred Stock Warrant (Right to Buy) |
M - Exercise | -60,576 | 0 | -100.00 | ||||
| 2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -755,263 | 0 | -100.00 | ||||
| 2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -486,316 | 0 | -100.00 | ||||
| 2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
F - Taxes | -39,063 | 1,952,139 | -1.96 | 8.00 | -312,504 | 15,617,112 | |
| 2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
F - Taxes | -39,063 | 1,952,139 | -1.96 | 8.00 | -312,504 | 15,617,112 | |
| 2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
M - Exercise | 60,576 | 1,991,202 | 3.14 | 5.16 | 312,572 | 10,274,602 | |
| 2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
M - Exercise | 60,576 | 1,991,202 | 3.14 | 5.16 | 312,572 | 10,274,602 | |
| 2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
C - Conversion | 1,909,113 | 1,909,113 | |||||
| 2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
| 2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
| 2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
| 2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
| 2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
| 2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
| 2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
| 2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
| 2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
| 2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -27,500 | 0 | -100.00 | 14.00 | -385,000 | ||
| 2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -78,369 | 0 | -100.00 | 14.00 | -1,097,166 | ||
| 2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -7,313,241 | 0 | -100.00 | 14.00 | -102,385,374 | ||
| 2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -50,743 | 0 | -100.00 | 14.00 | -710,402 | ||
| 2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -2,972,678 | 0 | -100.00 | 14.00 | -41,617,492 | ||
| 2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series D Preferred Stock |
C - Conversion | -7,430 | 0 | -100.00 | ||||
| 2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series C Preferred Stock |
C - Conversion | -15,799 | 0 | -100.00 | ||||
| 2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series B Preferred Stock |
C - Conversion | -10,661 | 0 | -100.00 | ||||
| 2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series D Preferred Stock |
C - Conversion | -435,663 | 0 | -100.00 | ||||
| 2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series C Preferred Stock |
C - Conversion | -926,321 | 0 | -100.00 | ||||
| 2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series B Preferred Stock |
C - Conversion | -625,065 | 0 | -100.00 | ||||
| 2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Common Stock |
C - Conversion | 33,890 | 33,890 | |||||
| 2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Common Stock |
C - Conversion | 1,987,049 | 1,987,049 | |||||
| 2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Warrants to Purchase Common Stock |
M - Exercise | -1,367,020 | 0 | -100.00 | ||||
| 2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
F - Taxes | -765,532 | 2,972,678 | -20.48 | 14.00 | -10,717,448 | 41,617,492 | |
| 2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1,367,020 | 3,738,210 | 57.65 | 7.84 | 10,717,437 | 29,307,566 | |
| 2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Warrants to Purchase Common Stock |
M - Exercise | -23,317 | 0 | -100.00 | ||||
| 2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
F - Taxes | -13,058 | 50,743 | -20.47 | 14.00 | -182,812 | 710,402 | |
| 2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
M - Exercise | 23,317 | 63,801 | 57.60 | 7.84 | 182,805 | 500,200 | |
| 2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Warrant |
C - Conversion | 156 | 156 | |||||
| 2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Warrant |
C - Conversion | -156 | 0 | -100.00 | ||||
| 2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series C Preferred Stock |
C - Conversion | -9,469 | 0 | -100.00 | ||||
| 2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series B Preferred Stock |
C - Conversion | -3,535 | 0 | -100.00 | ||||
| 2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Warrant |
C - Conversion | 21,041 | 21,041 | |||||
| 2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Warrant |
C - Conversion | -21,041 | 0 | -100.00 | ||||
| 2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series C Preferred Stock |
C - Conversion | -1,276,243 | 0 | -100.00 | ||||
| 2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series B Preferred Stock |
C - Conversion | -476,464 | 0 | -100.00 | ||||
| 2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 13,004 | 13,004 | |||||
| 2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 1,752,707 | 1,752,707 | |||||
| 2014-01-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -2,230 | 34,907 | -6.00 | 6.56 | -14,629 | 228,990 |
| 2014-01-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -1,010 | 37,137 | -2.65 | 6.01 | -6,070 | 223,193 |
| 2014-01-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -204,315 | 3,590,931 | -5.38 | 6.56 | -1,340,306 | 23,556,507 |
| 2014-01-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -92,445 | 3,795,246 | -2.38 | 6.01 | -555,594 | 22,809,428 |
| 2013-12-19 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 25,000 | 25,000 | |||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Warrant to Purchase Common Stock |
J - Other | 6,008 | 6,008 | |||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Warrant to Purchase Series D Preferred Stock |
J - Other | -10,068 | 0 | -100.00 | ||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series D Preferred Stock |
C - Conversion | -38,941 | 0 | -100.00 | ||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series C Preferred Stock |
C - Conversion | -9,378 | 0 | -100.00 | ||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series B Preferred Stock |
C - Conversion | -6,071 | 0 | -100.00 | ||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Warrant to Purchase Common Stock |
J - Other | 352,351 | 352,351 | |||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Warrant to Purchase Series D Preferred Stock |
J - Other | -590,403 | 0 | -100.00 | ||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series D Preferred Stock |
C - Conversion | -2,283,114 | 0 | -100.00 | ||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series C Preferred Stock |
C - Conversion | -549,833 | 0 | -100.00 | ||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series B Preferred Stock |
C - Conversion | -356,111 | 0 | -100.00 | ||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Common Stock |
C - Conversion | 54,390 | 54,390 | |||||
| 2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Common Stock |
C - Conversion | 3,189,058 | 3,189,058 | |||||
| 2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Series C Preferred Stock |
C - Conversion | -5,053 | 0 | -100.00 | ||||
| 2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Series C Preferred Stock |
C - Conversion | -680,972 | 0 | -100.00 | ||||
| 2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Series B Preferred Stock |
C - Conversion | -17,677 | 0 | -100.00 | ||||
| 2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Series B Preferred Stock |
C - Conversion | -2,382,322 | 0 | -100.00 | ||||
| 2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Common Stock |
C - Conversion | 22,730 | 22,730 | |||||
| 2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Common Stock |
C - Conversion | 3,063,294 | 3,063,294 | |||||
| 2013-09-30 |
|
4 | EVOK |
Evoke Pharma Inc
Series A Preferred Stock |
C - Conversion | -19,006 | 0 | -100.00 | ||||
| 2013-09-30 |
|
4 | EVOK |
Evoke Pharma Inc
Series A Preferred Stock |
C - Conversion | -1,114,327 | 0 | -100.00 | ||||
| 2013-09-30 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
C - Conversion | 19,006 | 19,006 | |||||
| 2013-09-30 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
C - Conversion | 1,114,327 | 1,114,327 | |||||
| 2013-09-24 | 3 | EVOK |
Evoke Pharma Inc
Common Stock |
5,250 | ||||||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series D Preferred Stock |
C - Conversion | -7,407 | 0 | -100.00 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series C Preferred Stock |
C - Conversion | -2,899 | 0 | -100.00 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series B Preferred Stock |
C - Conversion | -4,233 | 0 | -100.00 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series E Preferred Stock |
C - Conversion | -225,913 | 0 | -100.00 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series D Preferred Stock |
C - Conversion | -894,120 | 0 | -100.00 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series C Preferred Stock |
C - Conversion | -270,568 | 0 | -100.00 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series B Preferred Stock |
C - Conversion | -394,969 | 0 | -100.00 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 7,407 | 14,920 | 98.59 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 2,899 | 7,513 | 62.83 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 4,233 | 4,614 | 1,111.02 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
P - Purchase | 750,000 | 2,571,117 | 41.18 | 4.00 | 3,000,000 | 10,284,468 | |
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 225,913 | 1,821,117 | 14.16 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 894,120 | 1,595,204 | 127.53 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 270,568 | 701,084 | 62.85 | ||||
| 2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 394,969 | 430,516 | 1,111.12 | ||||
| 2013-08-21 | 3 | RGDO |
Regado Biosciences Inc
Common Stock |
35,547 | ||||||||
| 2013-08-21 | 3 | RGDO |
Regado Biosciences Inc
Common Stock |
381 | ||||||||
| 2013-08-21 | 3 | RGDO |
Regado Biosciences Inc
Common Stock |
17,171 | ||||||||
| 2013-07-31 |
|
4/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 331,873 | 1,857,036 | 21.76 | 6.03 | 1,999,999 | 11,191,242 | |
| 2013-07-31 |
|
4/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 7,333 | 7,333 | 6.03 | 44,192 | 44,192 | ||
| 2013-07-31 |
|
4/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 988,285 | 988,285 | 6.03 | 5,955,801 | 5,955,801 | ||
| 2013-07-31 | 3/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
47,963 | ||||||||
| 2013-07-31 | 3/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
1,525,163 | ||||||||
| 2013-07-31 | 3/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
15,731 | ||||||||
| 2013-07-16 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 331,873 | 1,897,336 | 21.20 | 6.03 | 1,999,999 | 11,434,106 | |
| 2013-07-16 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 7,333 | 7,333 | 6.03 | 44,192 | 44,192 | ||
| 2013-07-16 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 988,285 | 988,285 | 6.03 | 5,955,801 | 5,955,801 | ||
| 2013-07-16 | 3 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
47,963 | ||||||||
| 2013-07-16 | 3 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
1,565,463 | ||||||||
| 2013-07-16 | 3 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
15,731 | ||||||||
| 2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Common Stock |
J - Other | 1,193 | 1,193 | |||||
| 2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Series A Preferred Stock |
J - Other | -8,346 | 0 | -100.00 | ||||
| 2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -30,462 | 0 | -100.00 | ||||
| 2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Common Stock |
J - Other | 70,042 | 70,042 | |||||
| 2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Series A Preferred Stock |
J - Other | -489,320 | 0 | -100.00 | ||||
| 2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -1,786,012 | 0 | -100.00 | ||||
| 2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
P - Purchase | 4,791 | 35,253 | 15.73 | 14.00 | 67,074 | 493,542 | |
| 2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
C - Conversion | 30,462 | 30,462 | |||||
| 2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
P - Purchase | 280,923 | 2,066,935 | 15.73 | 14.00 | 3,932,922 | 28,937,090 | |
| 2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
C - Conversion | 1,786,012 | 1,786,012 | |||||
| 2013-06-25 | 3 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
21,471 | ||||||||
| 2013-06-24 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -114 | 38,147 | -0.30 | 5.01 | -571 | 191,116 |
| 2013-06-24 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -10,516 | 3,887,691 | -0.27 | 5.01 | -52,685 | 19,477,332 |
| 2013-06-20 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -22,423 | 3,898,207 | -0.57 | 5.37 | -120,412 | 20,933,372 |
| 2013-06-20 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -32,855 | 3,920,630 | -0.83 | 5.40 | -177,417 | 21,171,402 |
| 2013-06-20 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -244 | 38,261 | -0.63 | 5.37 | -1,310 | 205,462 |
| 2013-06-20 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -359 | 38,505 | -0.92 | 5.40 | -1,939 | 207,927 |
| 2013-06-18 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -959 | 38,864 | -2.41 | 5.40 | -5,179 | 209,866 |
| 2013-06-18 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -425 | 39,823 | -1.06 | 5.03 | -2,138 | 200,310 |
| 2013-06-18 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -87,812 | 3,953,485 | -2.17 | 5.40 | -474,185 | 21,348,819 |
| 2013-06-18 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -38,897 | 4,041,297 | -0.95 | 5.03 | -195,652 | 20,327,724 |
| 2013-06-13 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -59 | 40,248 | -0.15 | 5.00 | -295 | 201,240 |
| 2013-06-13 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -5,337 | 4,080,194 | -0.13 | 5.00 | -26,685 | 20,400,970 |
| 2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -159,192 | 2,581,745 | -5.81 | 64.58 | -10,280,619 | 166,729,092 | |
| 2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -2,779 | 44,034 | -5.94 | 64.58 | -179,468 | 2,843,716 | |
| 2013-06-04 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Stock Option (Right to Buy) |
A - Award | 28,000 | 28,000 | |||||
| 2013-05-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | -232 | 40,307 | -0.57 | 4.50 | -1,044 | 181,382 | |
| 2013-05-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | -251 | 40,539 | -0.62 | 4.70 | -1,180 | 190,533 | |
| 2013-05-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | -21,276 | 4,085,531 | -0.52 | 4.50 | -95,742 | 18,384,890 | |
| 2013-05-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | -22,966 | 4,106,807 | -0.56 | 4.70 | -107,940 | 19,301,993 | |
| 2013-05-01 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Warrant to Purchase Common Stock |
J - Other | 85,777 | 85,777 | |||||
| 2013-05-01 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Warrant to Purchase Common Stock |
J - Other | 12,906 | 32,091 | 67.27 | ||||
| 2013-05-01 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Warrant to Purchase Common Stock |
J - Other | 17,895 | 44,495 | 67.27 | ||||
| 2013-05-01 |
|
4 | NONE |
Celator Pharmaceuticals Inc
Common Stock |
J - Other | 156,749 | 2,378,924 | 7.05 | ||||
| 2013-04-17 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -23,210 | 2,371,190 | -0.97 | 6.62 | -153,650 | 15,697,278 |
| 2013-04-17 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -71,578 | 7,313,241 | -0.97 | 6.62 | -473,846 | 48,413,655 |
| 2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -1,567 | 2,394,400 | -0.07 | 6.72 | -10,530 | 16,090,368 |
| 2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -11,386 | 2,395,967 | -0.47 | 6.71 | -76,400 | 16,076,939 |
| 2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12,217 | 2,407,353 | -0.50 | 6.52 | -79,655 | 15,695,942 |
| 2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -4,832 | 7,384,819 | -0.07 | 6.72 | -32,471 | 49,625,984 |
| 2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -35,114 | 7,389,651 | -0.47 | 6.71 | -235,615 | 49,584,558 |
| 2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -37,676 | 7,424,765 | -0.50 | 6.52 | -245,648 | 48,409,468 |
| 2013-03-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -4,374 | 2,419,570 | -0.18 | 5.35 | -23,401 | 12,944,700 |
| 2013-03-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -893 | 40,484 | -2.16 | 5.49 | -4,903 | 222,257 |
| 2013-03-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -13,490 | 7,462,441 | -0.18 | 5.35 | -72,172 | 39,924,059 |
| 2013-03-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -1,743 | 78,369 | -2.18 | 5.49 | -9,569 | 430,246 |
| 2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5,510 | 2,423,944 | -0.23 | 5.22 | -28,762 | 12,652,988 |
| 2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -7,925 | 2,429,454 | -0.33 | 5.19 | -41,131 | 12,608,866 |
| 2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -92 | 41,377 | -0.22 | 5.22 | -480 | 215,988 |
| 2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -134 | 41,469 | -0.32 | 5.19 | -695 | 215,224 |
| 2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -182 | 80,112 | -0.23 | 5.22 | -950 | 418,185 |
| 2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -261 | 80,294 | -0.32 | 5.19 | -1,355 | 416,726 |
| 2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -16,995 | 7,475,931 | -0.23 | 5.22 | -88,714 | 39,024,360 |
| 2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -24,442 | 7,492,926 | -0.33 | 5.19 | -126,854 | 38,888,286 |
| 2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -8,020 | 2,437,379 | -0.33 | 5.16 | -41,383 | 12,576,876 |
| 2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -9,636 | 2,445,399 | -0.39 | 5.28 | -50,878 | 12,911,707 |
| 2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -135 | 41,603 | -0.32 | 5.16 | -697 | 214,671 |
| 2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -163 | 41,738 | -0.39 | 5.28 | -861 | 220,377 |
| 2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -265 | 80,555 | -0.33 | 5.16 | -1,367 | 415,664 |
| 2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -318 | 80,820 | -0.39 | 5.28 | -1,679 | 426,730 |
| 2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -24,736 | 7,517,368 | -0.33 | 5.16 | -127,638 | 38,789,619 |
| 2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -29,719 | 7,542,104 | -0.39 | 5.28 | -156,916 | 39,822,309 |
| 2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5,020 | 2,455,035 | -0.20 | 5.36 | -26,907 | 13,158,988 |
| 2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -7,733 | 2,460,055 | -0.31 | 5.40 | -41,758 | 13,284,297 |
| 2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -85 | 41,901 | -0.20 | 5.36 | -456 | 224,589 |
| 2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -131 | 41,986 | -0.31 | 5.40 | -707 | 226,724 |
| 2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -166 | 81,138 | -0.20 | 5.36 | -890 | 434,900 |
| 2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -256 | 81,304 | -0.31 | 5.40 | -1,382 | 439,042 |
| 2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -15,480 | 7,571,823 | -0.20 | 5.36 | -82,973 | 40,584,971 |
| 2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -23,848 | 7,587,303 | -0.31 | 5.40 | -128,779 | 40,971,436 |
| 2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -6,346 | 2,467,788 | -0.26 | 5.38 | -34,141 | 13,276,699 |
| 2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -4,118 | 2,474,134 | -0.17 | 5.34 | -21,990 | 13,211,876 |
| 2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -107 | 42,117 | -0.25 | 5.38 | -576 | 226,589 |
| 2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -70 | 42,224 | -0.17 | 5.34 | -374 | 225,476 |
| 2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -210 | 81,560 | -0.26 | 5.38 | -1,130 | 438,793 |
| 2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -136 | 81,770 | -0.17 | 5.34 | -726 | 436,652 |
| 2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -19,569 | 7,611,151 | -0.26 | 5.38 | -105,281 | 40,947,992 |
| 2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12,700 | 7,630,720 | -0.17 | 5.34 | -67,818 | 40,748,045 |
| 2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5,154 | 2,478,252 | -0.21 | 5.32 | -27,419 | 13,184,301 |
| 2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12,701 | 2,483,406 | -0.51 | 5.22 | -66,299 | 12,963,379 |
| 2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -88 | 42,294 | -0.21 | 5.32 | -468 | 225,004 |
| 2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -215 | 42,382 | -0.50 | 5.22 | -1,122 | 221,234 |
| 2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -171 | 81,906 | -0.21 | 5.32 | -910 | 435,740 |
| 2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -420 | 82,077 | -0.51 | 5.22 | -2,192 | 428,442 |
| 2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -15,892 | 7,643,420 | -0.21 | 5.32 | -84,545 | 40,662,994 |
| 2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -39,168 | 7,659,312 | -0.51 | 5.22 | -204,457 | 39,981,609 |
| 2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -3,839 | 2,496,107 | -0.15 | 5.06 | -19,425 | 12,630,301 |
| 2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -4,039 | 2,499,946 | -0.16 | 5.01 | -20,235 | 12,524,729 |
| 2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -65 | 42,597 | -0.15 | 5.06 | -329 | 215,541 |
| 2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -69 | 42,662 | -0.16 | 5.01 | -346 | 213,737 |
| 2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -11,841 | 7,698,480 | -0.15 | 5.06 | -59,915 | 38,954,309 |
| 2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12,454 | 7,710,321 | -0.16 | 5.01 | -62,395 | 38,628,708 |
| 2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -127 | 82,497 | -0.15 | 5.06 | -643 | 417,435 |
| 2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -134 | 82,624 | -0.16 | 5.01 | -671 | 413,946 |
| 2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -1,651 | 46,813 | -3.41 | 24.51 | -40,466 | 1,147,387 | |
| 2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -2,132 | 48,464 | -4.21 | 24.69 | -52,639 | 1,196,576 | |
| 2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -417 | 50,596 | -0.82 | 24.44 | -10,191 | 1,236,566 | |
| 2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -98,349 | 2,740,937 | -3.46 | 24.51 | -2,410,534 | 67,180,366 | |
| 2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -126,868 | 2,839,286 | -4.28 | 24.69 | -3,132,371 | 70,101,971 | |
| 2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -24,783 | 2,966,154 | -0.83 | 24.44 | -605,697 | 72,492,804 | |
| 2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5,145 | 2,503,985 | -0.21 | 5.01 | -25,776 | 12,544,965 |
| 2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -7,635 | 2,509,130 | -0.30 | 5.01 | -38,251 | 12,570,741 |
| 2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -88 | 42,731 | -0.21 | 5.01 | -441 | 214,082 |
| 2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -130 | 42,819 | -0.30 | 5.01 | -651 | 214,523 |
| 2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -170 | 82,758 | -0.20 | 5.01 | -852 | 414,618 |
| 2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -253 | 82,928 | -0.30 | 5.01 | -1,268 | 415,469 |
| 2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -15,865 | 7,722,775 | -0.21 | 5.01 | -79,484 | 38,691,103 |
| 2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -23,548 | 7,738,640 | -0.30 | 5.01 | -117,975 | 38,770,586 |
| 2013-02-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -1,998 | 2,516,765 | -0.08 | 5.01 | -10,010 | 12,608,993 |
| 2013-02-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -34 | 42,949 | -0.08 | 5.01 | -170 | 215,174 |
| 2013-02-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -6,160 | 7,762,188 | -0.08 | 5.01 | -30,862 | 38,888,562 |
| 2013-02-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -66 | 83,181 | -0.08 | 5.01 | -331 | 416,737 |
| 2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -10,076 | 2,518,763 | -0.40 | 5.02 | -50,582 | 12,644,190 |
| 2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -2,967 | 2,528,839 | -0.12 | 5.00 | -14,835 | 12,644,195 |
| 2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -171 | 42,983 | -0.40 | 5.02 | -858 | 215,775 |
| 2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -51 | 43,154 | -0.12 | 5.00 | -255 | 215,770 |
| 2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -334 | 83,247 | -0.40 | 5.02 | -1,677 | 417,900 |
| 2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -99 | 83,581 | -0.12 | 5.00 | -495 | 417,905 |
| 2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -31,075 | 7,768,348 | -0.40 | 5.02 | -155,996 | 38,997,107 |
| 2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -9,148 | 7,799,423 | -0.12 | 5.00 | -45,740 | 38,997,115 |
| 2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -2,951 | 2,531,806 | -0.12 | 5.01 | -14,785 | 12,684,348 |
| 2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5,763 | 2,534,757 | -0.23 | 5.00 | -28,815 | 12,673,785 |
| 2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -51 | 43,205 | -0.12 | 5.01 | -256 | 216,457 |
| 2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -98 | 43,256 | -0.23 | 5.00 | -490 | 216,280 |
| 2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -98 | 83,680 | -0.12 | 5.01 | -491 | 419,237 |
| 2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -191 | 83,778 | -0.23 | 5.00 | -955 | 418,890 |
| 2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -9,100 | 7,808,571 | -0.12 | 5.01 | -45,591 | 39,120,941 |
| 2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -17,770 | 7,817,671 | -0.23 | 5.00 | -88,850 | 39,088,355 |
| 2013-02-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -9,769 | 2,540,520 | -0.38 | 4.85 | -47,380 | 12,321,522 |
| 2013-02-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -164 | 43,354 | -0.38 | 4.85 | -795 | 210,267 |
| 2013-02-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -30,134 | 7,835,441 | -0.38 | 4.85 | -146,150 | 38,001,889 |
| 2013-02-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -322 | 83,969 | -0.38 | 4.85 | -1,562 | 407,250 |
| 2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -18,537 | 2,550,289 | -0.72 | 4.71 | -87,309 | 12,011,861 |
| 2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -11,105 | 2,568,826 | -0.43 | 5.00 | -55,525 | 12,844,130 |
| 2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -314 | 43,518 | -0.72 | 4.71 | -1,479 | 204,970 |
| 2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -188 | 43,832 | -0.43 | 5.00 | -940 | 219,160 |
| 2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -57,165 | 7,865,575 | -0.72 | 4.71 | -269,247 | 37,046,858 |
| 2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -34,248 | 7,922,740 | -0.43 | 5.00 | -171,240 | 39,613,700 |
| 2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -613 | 84,291 | -0.72 | 4.71 | -2,887 | 397,011 |
| 2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -367 | 84,904 | -0.43 | 5.00 | -1,835 | 424,520 |
| 2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -15,320 | 2,579,931 | -0.59 | 5.27 | -80,736 | 13,596,236 |
| 2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -16,660 | 2,595,251 | -0.64 | 5.40 | -89,964 | 14,014,355 |
| 2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -260 | 44,020 | -0.59 | 5.27 | -1,370 | 231,985 |
| 2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -282 | 44,280 | -0.63 | 5.40 | -1,523 | 239,112 |
| 2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -47,247 | 7,956,988 | -0.59 | 5.27 | -248,992 | 41,933,327 |
| 2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -51,377 | 8,004,235 | -0.64 | 5.40 | -277,436 | 43,222,869 |
| 2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -507 | 85,271 | -0.59 | 5.27 | -2,672 | 449,378 |
| 2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -551 | 85,778 | -0.64 | 5.40 | -2,975 | 463,201 |
| 2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -13,790 | 2,611,911 | -0.53 | 5.38 | -74,190 | 14,052,081 |
| 2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -36,324 | 2,625,701 | -1.36 | 5.45 | -197,966 | 14,310,070 |
| 2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -234 | 44,562 | -0.52 | 5.38 | -1,259 | 239,744 |
| 2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -616 | 44,796 | -1.36 | 5.45 | -3,357 | 244,138 |
| 2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -456 | 86,329 | -0.53 | 5.38 | -2,453 | 464,450 |
| 2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -1,201 | 86,785 | -1.36 | 5.45 | -6,545 | 472,978 |
| 2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -42,525 | 8,055,612 | -0.53 | 5.38 | -228,784 | 43,339,193 |
| 2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -111,022 | 8,098,137 | -1.35 | 5.45 | -605,070 | 44,134,847 |
| 2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -25,354 | 2,662,025 | -0.94 | 5.11 | -129,559 | 13,602,948 |
| 2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -14,966 | 2,687,379 | -0.55 | 5.02 | -75,129 | 13,490,643 |
| 2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -430 | 45,412 | -0.94 | 5.11 | -2,197 | 232,055 |
| 2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -254 | 45,842 | -0.55 | 5.02 | -1,275 | 230,127 |
| 2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -839 | 87,986 | -0.94 | 5.11 | -4,287 | 449,608 |
| 2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -495 | 88,825 | -0.55 | 5.02 | -2,485 | 445,902 |
| 2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -78,188 | 8,210,159 | -0.94 | 5.11 | -399,541 | 41,953,912 |
| 2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -46,153 | 8,288,347 | -0.55 | 5.02 | -231,688 | 41,607,502 |
| 2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -19,080 | 2,702,345 | -0.70 | 5.19 | -99,025 | 14,025,171 |
| 2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12,615 | 2,721,425 | -0.46 | 5.35 | -67,490 | 14,559,624 |
| 2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -324 | 46,096 | -0.70 | 5.19 | -1,682 | 239,238 |
| 2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -214 | 46,420 | -0.46 | 5.35 | -1,145 | 248,347 |
| 2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -58,838 | 8,334,500 | -0.70 | 5.19 | -305,369 | 43,256,055 |
| 2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -38,903 | 8,393,338 | -0.46 | 5.35 | -208,131 | 44,904,358 |
| 2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -631 | 89,320 | -0.70 | 5.19 | -3,275 | 463,571 |
| 2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -418 | 89,951 | -0.46 | 5.35 | -2,236 | 481,238 |
| 2013-01-18 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | 66,462 | 159,896 | 71.13 | ||||
| 2013-01-18 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | -1,000,000 | 5,772,968 | -14.76 | ||||
| 2013-01-15 | 3 | NONE |
Celator Pharmaceuticals Inc
Common Stock |
2,222,175 | ||||||||
| 2013-01-15 | 3 | NONE |
Celator Pharmaceuticals Inc
Common Stock |
16,733 | ||||||||
| 2013-01-15 | 3 | NONE |
Celator Pharmaceuticals Inc
Common Stock |
5,868 | ||||||||
| 2012-12-20 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 20,000 | 20,000 | |||||
| 2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -16,529 | 0 | -100.00 | ||||
| 2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -2,227,596 | 0 | -100.00 | ||||
| 2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
P - Purchase | 5,777 | 22,306 | 34.95 | 9.00 | 51,993 | 200,754 | |
| 2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
C - Conversion | 16,529 | 16,529 | |||||
| 2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
P - Purchase | 778,536 | 3,006,132 | 34.95 | 9.00 | 7,006,824 | 27,055,188 | |
| 2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
C - Conversion | 2,227,596 | 2,227,596 | |||||
| 2012-07-18 | 3 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
6,250 | ||||||||
| 2012-06-04 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | 93,434 | 93,434 | |||||
| 2012-06-04 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | -1,200,000 | 6,772,968 | -15.05 | ||||
| 2004-05-12 | 3 | NUVA |
NUVASIVE INC
Common Stock |
8,000 |
